ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Naresh Somani
Background: Head and neck cancers (HNCs) constitute 5% of all cancers globally and are the most common cancers in India. Chemotherapy and radiotherapy have not been proved to be effective in advanced cases and the prognosis remains dismal. This underscores th…
Maria Toloudi, Panagiotis Apostolou, Ioannis Papasotiriou
Recent clinical and research development supports the use of 5-fluorouracil in combination with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5-Fluorouracil (5-FU), which is as an anti-metabolite, is a widely used cytostatic…
Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek
Inoperable brainstem gliomas (BSG) are among the most difficult to treat malignancies. In the intent-to-treat (ITT) population of the BT-11 study for BSG, forty patients (median age 11.2 years old) were enrolled. Antineoplastons A10 and AS2-1 (ANP) were admin…
Matthew H. Taylor, Alan Sandler, Walter J. Urba, Antonio M. P. Omuro, Greg S. Gorman, Rashida A. Karmali, 1 1
Pre-clinical studies suggest carboxyamidotriazole orotate (CTO) demonstrates anti-tumor activity through modulation of multiple tyrosine kinase signaling pathways and interactions with the tumor microenvironment. We determined the safety and tolerability, pha…
Sandi Shen, Shizhen Zhong, Hai Lu, Wenhua Huang, Gaofang Xiao
Objectives: The invasive breast cancer is divided into four clinical subtypes: Luminal A-like, Luminal B-like, HER-2 positive, and triple-negative according to the expression status of estrogen receptor (ER), progesterone receptor(PR), human epidermal growth…
Nahla Ali Mobark, Suha A. Tashkandi, Wafa Al Shakweer, Khalid Al Saidi, Suha A. Fataftah, Mohammed M. Al Nemer, Awatif Alanazi, Mohammed Rayis, Walid Ballourah, Othman Mosleh, Zaheer Ullah, Fahad El Manjomi, Musa Al Harbi
Background: Non-Hodgkin’s lymphoma is an aggressive malignant disease in children and adolescents. Although it is the fourth most common malignancy in Saudi children as reported in Saudi cancer registry, less information is available about pediatric Non-Hodgk…
Qianhe Liao, Shuhong Hu
Meigs’ syndrome represents a triad of pleural effusion, ascites, and an ovarian tumor, which is usually benign, occurring together. We describe here 2 patients with Meigs’ syndrome and 2 patients with pseudo-Meigs’ syndrome. Hydrothorax and ascites symptoms i…
Fernando Gomes Romeiro, Luciana Yumi Odani Sigahi, Matheus Alvarez, Fabio da Silva Yamashiro, Fábio Cardoso de Carvalho, Leonardo Pelafsky, Talles Bazeia Lima, Letícia de Campos Franzoni, José Ricardo de Arruda Miranda, Giovanni Faria Silva
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of mortality among cirrhotic patients, and current guidelines recommend single-treatment modalities according to patient and liver disease classifications. New studies have shown promising result…
Hiroyuki Kogai, Shinji Kikuchi, Takashi Obana, Yumi Tsuboi, Tomoko Maruyama, Mika Sakurai-Yageta, Hisao Asamura, Yae Kanai, Yoshinori Murakami
Objective: Targeting mutated EGFR by EGFR-tyrosine kinase inhibitors (EGFR-TKI) is a potent approach to a subset of non-small cell lung cancer (NSCLC). However, the response to EGFR-TKI varies in individual cases even among tumors carrying the same EGFR mutat…
Aaron J. Smith, John Oertle, Dino Prato
Curcumin is a naturally occurring phytotherapeutic that has broad uses including the treatment of cancer and as a potent antimicrobial agent. Its dynamic ability to treat very different kinds of disease has spawned a significant increase in inquiry on how cur…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).